Partner

Industrial collaboration partners
Cilian offers to partner with pharma and biotechnology companies in the application of its technology platform, the Ciliates based CIPEX-System, for feasibility studies and in-licensing.

Cilian is already collaborating with Proinnovera GmbH, a German CRO, in order to prepare the clinical development of the human flu vaccine Ciflu®.
Please have look to our press release (English).

Cilian also develops its own projects, such as a recombinant flu vaccine, a biobetter monoclonal antibody and an enzyme preparation for pancreatic insufficiency. For these projects, Cilian is actively seeking collaboration partners that can obtain worldwide distribution rights.

 

Investors
Since its incorporation in 2001 the company received funding from various venture capital firms and private investors. In 2006 the majority of shares in Cilian AG were acquired by Schneberger Beteiligungs GmbH and Co KG, a private-investor from Münster (Germany).
Cilian AG also received grants in the amount of € 1.9 million from state of North Rhine-Westphalia (Germany), the German Federal Ministry for Education and Research, the German Federal Ministry of Economics and Technology and the European Commission.

 

Academic collaborators
Within the framework of close collaborations with various academic groups across Europe we offer our scientific expertise to our academic partners, in order to jointly advance applied Ciliate research.

Prof. Dr. Arno Tiedtke,
Institute for general Zoology and Genetics, Westfälische Wilhelms University, Münster, Germany

Professor Tiedtke is one of the prominent specialists in the area of the study of the phagosomal Proteoms of the Ciliate Tetrahymena. Research within his working group contributed extensively for many years to the elucidation of the steering control of lysosomal enzymes. A number of biotechnological methods and processes for the production of lysosomal enzymes were developed for the first time as a result of these investigations (high cell density fermentation of Ciliates, strain development and purification protocols).

Dr. Jürgen Schnekenburger,
Biomedical Technology Center of the Medical Faculty Münster

Acting as a link between medicine and nanobiotechnology, the Biomedical Technology Center works on the development and application of novel technologies in medical research and diagnostics. The interdisciplinary team is qualified in establishing new methods and test systems. The Biomedical Technology Center has its origin in a pancreas research group and is therefore very experienced in the field of pancreatitis research and the application of pancreatitis animal models.
» external link
„Academic cooperation partner of Cilian AG in the Cilase®-project“

Prof. Dr. med. Waldemar Uhl,
Pancreas Center at St. Josef-Hospital Bochum, Clinic of the Ruhr University Bochum

The surgical center is part of a maximum care hospital with a focus on research. The hospital is the surgical partner of the Pancreas Center of Bochum which serves as a first point of contact for patients from greater North Rhine-Westphalia. The hospital employees are specialized in the treatment and research in the field of pancreatic diseases. The success in this area is documented in numerous publications. The surgical center services the largest pool of patients in North Rhine-Westphalia and serves therefore as one of the main contact points for clinical studies and clinical research in the field of the exocrine pancreas. Since 2004 a center for pancreatic diseases of European importance is working at the St. Josef-Hospital, Clinic of the Ruhr University. 1411 pancreatic surgeries have been performed here until december 2009.
» external link
„Academic cooperation partner of Cilian AG in the Cilase®-project“

Dr. Marco Bruno,
Department of Gastroenterology and Hepatology, Academic Medical Center Amsterdam, The Netherlands

Dr. Bruno is a prominent specialist and physician for Gastroenterology at AMC at the University of Amsterdam (the Netherlands). As physician he leads a research group, with a focus on the treatment of liver, pancreas and gall bladder abnormalities. Focus of the research work is the epidemiology, risk factors, genetics of acute and chronic pancreatitis, as well as animal models and the development of new diagnostic and working methods for acute pancreatitis.

Dr. David Cavanagh,
Institute of Cell, Animal and Population Biology, University of Edinburgh, Edinburgh, Scotland

Dr. Cavanagh is lecturer and head of a scientific working group at the University of Edinburgh in one of the most prominent scientific institutes in Great Britain. Dr. Cavanagh has over 10 years experience in malaria research and is author of several patent applications in the area of malaria vaccines, which are based on the surface protein MSP-1. The focus of his working group is on the immune-biology of the malaria parasite, coupled with malaria studies in Africa, with the aim to develop better or new vaccines.
» external link
„Academic collaboration partner (Contractor) of Cilian AG in the “ CILMALVAC-Project“

Prof. Dr. Thor Theander,
Centre for Medical Parasitology, University of Copenhagen, Copenhagen, Denmark

Dr. Theander is a professor at the center for medical parasitology at the University of Copenhagen, a research institute with emphasis on the interaction between the malaria parasite and the human host specifically during the pregnancy. The institute has developed two vaccine candidates against malaria, the proteins VAR2CSA and VAR4, and filed patent applications for their findings. Professor Theander is involved with the European malaria vaccine initiative and leads the group for vaccine development with extensive collaborations with research groups in Sudan, Ghana, Tanzania and China.
» external link
„Academic collaboration partner (Contractor) of Cilian AG in the CILMALVAC-Projekt“